If you pay in Bitcoin, you will get a -2% Discount on your order!
CJC-1295 with DAC (2 mg) – Research Peptide Guide
1. Compound Overview
CJC-1295 with DAC (Drug Affinity Complex) is an advanced growth hormone-releasing hormone (GHRH) analog engineered for sustained release, providing prolonged elevation of endogenous growth hormone (GH) and IGF-1 levels compared to its non-DAC counterpart.
2. Scientific Mechanism
Extended Half-Life: DAC modification allows slow release over 7-10 days per injection.
Pituitary Stimulation: Binds to GHRH receptors, triggering natural pulsatile GH secretion.
IGF-1 Upregulation: Enhances anabolic effects through insulin-like growth factor activation.
3. Research Applications & Benefits
Muscle Growth: Promotes hypertrophy & protein synthesis via increased GH/IGF-1.
Fat Loss: Accelerates lipolysis while preserving lean mass.
Tissue Repair: Stimulates collagen production for joint/tendon recovery.
Anti-Aging: May improve skin elasticity & sleep quality through GH-mediated regeneration.
4. Administration Protocol
Dosage: 1-2 mg weekly (single or split doses).
Route: Subcutaneous or intramuscular injection.
Cycle Duration: 8-12 weeks (optimal for sustained effects).
5. Potential Side Effects
Water Retention (mild, transient).
Carpal Tunnel-like Symptoms (dose-dependent nerve pressure).
Insulin Sensitivity Changes (monitor glucose if combining with metabolic peptides).
6. Synergistic Combinations
Ipamorelin: Enhances pulsatile GH release without desensitization.
Tesamorelin: For targeted fat reduction (visceral adipose tissue).
HGH Fragment 176-191: Focuses lipolytic effects.
7. Purchase Information
Available in 2 mg lyophilized vials (99% purity) for research purposes only.
Disclaimer: This product is not for human or veterinary use—intended solely for laboratory study.
